# Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

> **NCT05724446** · PHASE3 · RECRUITING · sponsor: **Salvat** · enrollment: 60 (estimated)

## Conditions studied

- Cataracts Infantile

## Interventions

- **DRUG:** Clobetasol Propionate
- **DRUG:** Prednisolone acetate ophthalmic suspension, 1%

## Key facts

- **NCT ID:** NCT05724446
- **Lead sponsor:** Salvat
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-12
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724446, "Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05724446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*